From Rat Cages to Global Biotech: The Rise and Controversies of Charles River Laboratories

In this episode, we trace the evolution of Charles River Laboratories, an American corporation that began in 1947 when a young veterinarian set up a one-person laboratory with one thousand rat cages overlooking the Charles River in Boston. We discuss how the company grew from a local supplier of laboratory animals into a massive contract research organization (CRO) headquartered in Wilmington, Massachusetts, that now employs over 20,000 people across at least 20 countries.

Listeners will learn about the company’s pivotal role in supporting the pharmaceutical and biotechnology industries by providing preclinical and clinical services for the development of new drugs, vaccines, and medical devices. We analyze their aggressive growth strategy, highlighting key acquisitions—such as Inveresk, MPI Research, and Cognate BioServices—that expanded their capabilities into gene therapy and antibody discovery, as well as their failed 2010 bid to acquire WuXi PharmaTech.

Finally, we examine the ethical challenges facing this S&P 500 component, including ongoing public scrutiny and regulatory attention regarding its use of laboratory animals like primates, dogs, and horseshoe crabs. We also cover the company’s internal responses to these concerns, such as the 2002 launch of the "Humane Care Imperative" to train employees on animal welfare.

Key Topics:

• Origins: Founded by Henry Foster in 1947 to supply researchers with animal models.
• Business Model: A leading CRO conducting toxicology studies and safety assessments for FDA regulatory submissions.
• Expansion: A history of major acquisitions, including the move into cell and gene therapy markets.
• Controversy: Protests regarding animal testing practices and the export of endangered macaques.
• Financials: A publicly traded powerhouse on the NYSE with 2024 revenues of $4.05 billion.